P/E ratio for Onconova Therapeutics (ONTX)
P/E ratio as of March 2023 (TTM): -0.8966
According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.896552. At the end of 2014 the company had a P/E ratio of -1.12.
P/E ratio history for Onconova Therapeutics from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2014 | -1.12 | -64.64% |
| 2013 | -3.15 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Baxter BAX | -7.88 | 779.03% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -1.26 | 41.06% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -4.10 | 357.41% | 🇺🇸 USA |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Array Technologies ARRY | -44.1 | 4,816.27% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.